Phillip Northcross
Internal Medicine · Memphis, TNNPI 1831166677
Payments from drug & device makers
Across 571 payments — averaging $68.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$21K
- Johnson & Johnson$7K
- Lilly USA, LLC$2K
- Boehringer Ingelheim$2K
- Esperion Therapeutics, Inc.$1K
- Sanofi-aventis U.S. LLC$1K
- plus $6K from 21 others
What the payments were for
- Speaking & faculty fees$21,75056%
- Travel & lodging$1,1313%
- Food & beverage$16,21941%
- Education$260%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 131 | $21,494 |
| Johnson & Johnson | 20 | $6,612 |
| Lilly USA, LLC | 89 | $1,555 |
| Boehringer Ingelheim | 66 | $1,510 |
| Esperion Therapeutics, Inc. | 27 | $1,272 |
| Sanofi-aventis U.S. LLC | 49 | $1,218 |
| Kowa Pharmaceuticals America, Inc. | 42 | $687 |
| Merck | 42 | $685 |
| GSK | 26 | $589 |
| Bayer | 12 | $509 |
| Abbott | 4 | $508 |
| Amgen | 8 | $358 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $354 |
| Novo Nordisk | 3 | $267 |
| Mannkind Corporation | 7 | $246 |
| Janssen Scientific Affairs, LLC | 2 | $221 |
| Medtronic(2 entities) | 2 | $159 |
| Shield Therapeutics Inc | 8 | $158 |
| Novartis | 3 | $137 |
| Madrigal Pharmaceuticals | 1 | $131 |
| Amarin Pharma, Inc. | 1 | $112 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Arbor Pharmaceuticals, Inc. | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $80 |
| Nalpropion Pharmaceuticals LLC | 4 | $67 |
| Antares Pharma, Inc. | 3 | $46 |
| AbbVie(2 entities) | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$17,684
- INVOKANA$6,613
- FARXIGA$1,711
- NEXLIZET$820
- NEXLETOL$820
- BREZTRI$765
- Kerendia$336
- JARDIANCE$334
- FreeStyle Libre Pro$249
- PRALUENT$233
- Repatha$230
- FreeStyle Libre$144
- REZDIFFRA$131
- RYBELSUS$123
- AFREZZA$118
- SOLIQUA 100/33$117
- Diamondback Peripheral$115
- Vascepa$112
- MOUNJARO$106
- STEGLATRO$105
How this compares
$39,186 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 125 | $158,205 |
| FarxigaDapagliflozin Propanediol | 59 | $63,942 |
| JardianceEmpagliflozin | 60 | $44,001 |
| TradjentaLinagliptin | 21 | $23,592 |
| XareltoRivaroxaban | 13 | $19,395 |
| EliquisApixaban | 19 | $18,930 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $15,076 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $13,342 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $8,584 |
| Colesevelam Hcl | 14 | $6,662 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 26 | $3,644 |
| Ezetimibe | 111 | $2,237 |
| Potassium Chloride | 96 | $2,174 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 28 | $1,579 |
| Rosuvastatin Calcium | 110 | $1,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,555 | $158,205125 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $1,510 | $80,935103 claims |
| AstraZenecaFarxiga | $21,494 | $63,94259 claims |
| Johnson & JohnsonXarelto | $6,612 | $19,39513 claims |
| GSKTrelegy Ellipta | $589 | $15,07620 claims |
| MerckJanumet Xr | $685 | $8,58411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Memphis
- Lawrence WhitlockMemphis$36K
- Angela WatsonMemphis$32K
- William CushmanMemphis$24K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.